Vaccines against bovine babesiosis: where we are now and possible roads ahead

Abstract

SUMMARYBovine babesiosis caused by the tick-transmitted haemoprotozoansBabesia bovis, Babesia bigeminaandBabesia divergenscommonly results in substantial cattle morbidity and mortality in vast world areas. Although existing live vaccines confer protection, they have considerable disadvantages. Therefore, particularly in countries where large numbers of cattle are at risk, important research is directed towards improved vaccination strategies. Here a comprehensive overview of currently used live vaccines and of the status quo of experimental vaccine trials is presented. In addition, pertinent research fields potentially contributing to the development of novel non-live and/or live vaccines are discussed, including parasite antigens involved in host cell invasion and in pathogen-tick interactions, as well as the protective immunity against infection. The mining of available parasite genomes is continuously enlarging the array of potential vaccine candidates and, additionally, the recent development of a transfection tool forBabesiacan significantly contribute to vaccine design. However, the complication and high cost of vaccination trials hinderBabesiavaccine research, and have so far seriously limited the systematic examination of antigen candidates and prevented an in-depth testing of formulations using different immunomodulators and antigen delivery systems.